Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
March 28, 2023
Assignee:
HANALL BIOPHARMA CO., LTD.
Inventors:
Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
March 21, 2023
Assignee:
GENMAB A/S
Inventors:
Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
Abstract: Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “?CD28×?B7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject ?CD28×?B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
Type:
Grant
Filed:
December 21, 2021
Date of Patent:
February 28, 2023
Assignee:
Xencor, Inc.
Inventors:
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.
Type:
Grant
Filed:
April 28, 2020
Date of Patent:
January 10, 2023
Assignee:
Invetx, Inc.
Inventors:
William Brondyk, Brett Chevalier, Juergen Horn, Madhusudan Natarajan
Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
December 13, 2022
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Peter Bruenker, Frank Herting, Sylvia Herter, Christian Klein, Ekkehard Moessner, Tilman Schlothauer
Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
November 22, 2022
Assignees:
argenx BV, The Board of Regents of the University of Texas System
Inventors:
Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
Abstract: The invention is directed to engineered Fc gamma receptor type III (Fc?II, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
October 4, 2022
Assignee:
One Lambda, Inc.
Inventors:
Jar-How Lee, Neng Jen Remi Shih, Julie Nguyen, Rui Pei
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Grant
Filed:
November 21, 2011
Date of Patent:
September 20, 2022
Assignee:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Grant
Filed:
November 10, 2011
Date of Patent:
September 6, 2022
Assignee:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
August 30, 2022
Assignee:
Amgen Inc.
Inventors:
Zhimei Du, Pranhitha Reddy, Randal B. Bass, Feng He, William C. Fanslow, III, Yuling Zhang, Da Ren, Randal R. Ketchem
Abstract: Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically binds to a target using a transpeptidase for enzymatic conjugation of the antibody Fc-region to at least one binding entity.
Abstract: The present disclosure relates to a polypeptide containing an Fc domain in which a part of an amino acid sequence of a human antibody Fc domain is substituted with another amino acid sequence, or an aglycosylated antibody containing the same. The Fc domain of the present disclosure is optimized by substituting a part of an amino acid sequence of a wild-type Fc domain with another amino acid sequence. Therefore, it is useful in treatment of cancer due to superior selective binding ability to Fc?RIIIa among Fc receptors, and can be prepared as a homogeneous aglycosylated antibody through bacterial culture.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
August 16, 2022
Assignee:
KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
Type:
Grant
Filed:
February 8, 2019
Date of Patent:
July 12, 2022
Inventors:
Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
July 12, 2022
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
June 14, 2022
Assignee:
Alector LLC
Inventors:
Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
Type:
Grant
Filed:
March 5, 2015
Date of Patent:
June 7, 2022
Inventors:
Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
May 17, 2022
Assignees:
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
Inventors:
So-Young Eun, Miyoung Oh, Hye-Young Park, Mijung Lee, Aerin Yoon, Hye In Yum, Hyemi Nam, Eunhee Lee, Jongwha Won
Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc?RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.